New pill targets hidden inflammation to fight diabetes

NCT ID NCT06047262

Recruiting now Disease control Sponsor: Marc Donath Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new oral drug called dapansutrile can help manage type 2 diabetes. The drug works by targeting a specific source of inflammation in the body, which researchers believe contributes to high blood sugar and related complications. About 300 adults with type 2 diabetes will take either the drug or a placebo for 3-4 months to see if it improves blood sugar control and reduces markers of inflammation.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU de Liege
RECRUITING

Liège, 4000, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
Deutsches Zentrum für Diabetesforschung Düsseldorf
RECRUITING

Düsseldorf, Nordrhein-Westphalen, 40225, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••
Hopital Bichat
RECRUITING

Paris, Île-de-France Region, 75018, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Hopital Lariboisiere
RECRUITING

Paris, Île-de-France Region, 75010, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Kantonsspital Olten
RECRUITING

Olten, Canton of Solothurn, 4600, Switzerland

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Hospital Basel
TERMINATED

Basel, Basel, 4031, Switzerland

Conditions

Explore the condition pages connected to this study.

DIABETES MELLITUS TYPE 2